Investor in Novanta (NASDAQ: NOVT) to sell 6,500 Rule 144 shares

Rhea-AI Filing Summary

Matthijs Glastra filed a notice to sell 6,500 shares of Novanta, Inc. common stock under Rule 144. The shares have an aggregate market value of $878,461, are listed on NASDAQ, and the approximate sale date is 02/02/2026, using Merrill Private Wealth Management as broker.

The filing shows these shares relate to restricted stock units granted as equity compensation on 02/24/2023, 02/26/2024, and 01/02/2025. It also lists recent sales of Novanta common stock by the same person during the past three months, including transactions on 01/08/2026, 01/09/2026, and 01/21/2026 with disclosed gross proceeds.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Private Wealth Management 100 Federal Street, 12th Floor Boston MA 02110	6500	878461	35775123	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/26/2024	Restricted Stock Units	Novanta, Inc.			370	02/26/2024	Equity Compensation
Common	02/24/2023	Restricted Stock Units	Novanta, Inc.			80	02/24/2023	Equity Compensation
Common	01/02/2025	Restricted Stock Units	Novanta, Inc.			6050	01/02/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matthijs Glastra C/O Novanta, Inc. 125 Middlesex Turnpike Bedford MA 01730	Common	01/08/2026	323	41990
Matthijs Glastra C/O Novanta, Inc. 125 Middlesex Turnpike Bedford MA 01730	Common	01/09/2026	6177	803010
Matthijs Glastra C/O Novanta, Inc. 125 Middlesex Turnpike Bedford MA 01730	Common	01/21/2026	7500	1050000

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Novanta (NOVT) Form 144 filing disclose about upcoming share sales?

The filing discloses a proposed sale of 6,500 Novanta common shares under Rule 144, with an aggregate market value of $878,461. The shares are to be sold through Merrill Private Wealth Management on NASDAQ, with an approximate sale date of 02/02/2026.

How many Novanta (NOVT) shares were sold in the past three months?

The notice lists three past sales of Novanta common stock by the same person during the last three months: 323 shares on 01/08/2026, 6,177 shares on 01/09/2026, and 7,500 shares on 01/21/2026, with gross proceeds reported for each transaction.

How were the Novanta (NOVT) shares in the Form 144 acquired?

The shares referenced in the notice were acquired through restricted stock units granted as equity compensation by Novanta, Inc. Grants occurred on 02/24/2023, 02/26/2024, and 01/02/2025, with specific amounts of common stock tied to each grant date and paid in equity.

What is the market value and exchange for the Novanta (NOVT) shares to be sold?

The proposed 6,500 Novanta common shares have an aggregate market value of $878,461 according to the filing. The securities are listed for trading on NASDAQ, and Merrill Private Wealth Management is named as the broker handling the planned sale.

What does the Rule 144 representation state in the Novanta (NOVT) notice?

The person for whose account the securities will be sold represents by signing that they do not know any material adverse information about Novanta’s current or prospective operations that has not been publicly disclosed, as required under the Rule 144 notice language.